Skip to main content
SpringerLink
Log in
Book cover

Antitumor Antibiotics pp 288–297Cite as

Clinical Evaluation of New Antitumor Antibiotics

  • Chapter

  • 134 Accesses

Abstract

In the field of antimicrobial antibiotics, the initial discovery of several active compounds was followed by an era of exploration of modifications on the basic structures. These modifications, in the case of the penicillins, led to changes in pharmacology, important improvements in the therapeutic index and, later, to dramatic changes in the therapeutic spectrum. Similar developments are occurring and may be expected to increase rapidly among the antitumor antibiotics. From relatively minor modifications, it is likely that we shall witness bolder structural alterations of currently active antibiotics based on additional understanding of mechanisms of action.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson, T., Mcmenamin, M. G., Schein, P. S.: Chlorozotocin, 2-[3-(chloroethyl)-3-nitrosoureido]-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res. 35, 761–765 (1975).

    PubMed  CAS  Google Scholar 

  2. Atassi, G., Tagnon, H. J., Staquet, M.: Comparison of adriamycin (NSC 123127) and DNA-adriamycin complex in the chemotherapy of experimental tumors and metastases. In: E.O.R.T.C. International Symposium on Adriamycin Review. Ghent: European Press Medikon 1975, pp. 70–78.

    Google Scholar 

  3. Beisler, J. A., Hepp, P. L., Quinn, F. R., Driscoll, J.S.: 5-Azacytidine decomposition in aqueous solution: Isolation and characterization of the N-formyl hydrolysis intermediate (Abst. 682). Proc. Am. Assoc. Cancer Res. 18, 171 (1977).

    Google Scholar 

  4. Bernard, J., Jacquillat, C. L., Boiron, M., Weil, M., Geman, M. F., Izrael, V., Schaison, G., Delobel, J.: Observations de leucémies aigues. Essai de traitement pour un dérivé semi-synthétique de la daunorubicine. Nouv. Presse. Med. 1, 2149–2152 (1972).

    PubMed  CAS  Google Scholar 

  5. BoRisov, V. I., Lipatov, A. M., Perevodchikova, N. I., et al.: Results of a cooperative clinical study of a new cancer chemotherapy antibiotic, carminomycin. Submitted to Antibiotiki (1976).

    Google Scholar 

  6. Carter, S. K., Ichikawa, T., Mathe, G., Umezawa, H. (eds.): Fundamental and Clinical Studies of Bleomycin. Gann Monograph on Cancer Research No. 19. Tokyo: University of Tokyo Press 1976.

    Google Scholar 

  7. Dimarco, A., Casazza, A. M., Gambetta, R., Supino, R., Zunino, F.: Relationship between activity and amino sugar stereochemistry of daunorubicin and adriamycin derivatives. Cancer Res. 36, 1962–1966(1976).

    CAS  Google Scholar 

  8. Friedman, M. A., Bozdech, M. K., Billingham, M., Rider, A.: Adriamycin cardiotoxicity in humans: Serial physiologic studies and endomyocardial biopsy. Clin. Res. 25, 407A (1977).

    Google Scholar 

  9. Furue, H.: Phase I trial with aclacinomycin A. Proc. Jap. Cancer Assoc, 35th Annual Mtg., Abst. 416, October 1976.

    Google Scholar 

  10. Goldin, A., Johnson, R. K.: Evaluation of actinomycins in experimental systems. Cancer Chemother. Rep. 58, 63–77 (1974).

    PubMed  CAS  Google Scholar 

  11. Greco, F. A., Brereton, H. D., Rodbard, D.: Noninvasive monitoring of adriamycin cardiotoxicity by ‘Sphygmo-Recording’ of the pulse wave delay (QKd interval). Cancer Treat. Rep. 60, 1239–1245(1976).

    PubMed  CAS  Google Scholar 

  12. Henney, J., Von Hoff, D. D., Rozencweig, M., Muggia, F. M.: Cancerostatic analogues, the same or different? Clin. Pharmacol. Ther. 21, 106 (1977).

    Google Scholar 

  13. Inaba, M., Johnson, R. K., Goldin, A.: Uptake and retention of 3H-actinomycin in sublines of P388 leukemia resistant to adriamycin and daunorubicin. (Abst. 610) Proc. Am. Assoc. Cancer Res. 18, 153 (1977).

    Google Scholar 

  14. Israel, M., Modest, E. J., Frei, E.: N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 35, 1365–1368 (1975).

    PubMed  CAS  Google Scholar 

  15. Katz, E.: Controlled biosynthesis of actinomycins. Cancer Chemother. Rep. 58, 83–91 (1974).

    PubMed  CAS  Google Scholar 

  16. Livingston, R. B., Venditti, J. W., Cooney, D., Carter, S. K.: Glutamine antagonists in chemotherapy. Adv. Pharmacol. Chemother. 8, 57–120 (1970).

    Article  PubMed  CAS  Google Scholar 

  17. Meienhofer, J.: Synthesis of peptide analogs of actinomycin D (NSC-3053). Cancer Chemother. Rep. 58, 21–34 (1974).

    PubMed  CAS  Google Scholar 

  18. Minow, R. A., Benjamin, R. S., Lee, E. T., Gottlieb, J. A.: Adriamycin cardiotoxicity—Risk factors. Cancer 39, 1397–1402 (1977).

    Article  PubMed  CAS  Google Scholar 

  19. Modest, E. J., Sengupta, S. K.: 7-Substituted actinomycin D (NSC-3053) analogs as fluorescent DNA-binding and experimental antitumor agents. Cancer Chemother. Rep. 58, 35–48 (1974).

    PubMed  CAS  Google Scholar 

  20. Myers, C. E., Mcguire, W., Young, R.: Adriamycin: Amelioration of toxicity by α-tocopherol. Cancer Treat. Rep. 60, 961–962 (1976).

    PubMed  CAS  Google Scholar 

  21. Ramos, A., Meyer, R. A., Korfhagen, J., Wong, K. Y., Kaplan, S.: Echocardiographic evaluation of adriamycin cardiotoxicity in children. Cancer Treat. Rep. 60, 1281–1284 (1976).

    PubMed  CAS  Google Scholar 

  22. Rinehart, J. J., Lewis, R. P., Balcerzak, S. P.: Adriamycin cardiotoxicity in man. Ann. Intern. Med. 81, 475–478 (1974).

    PubMed  CAS  Google Scholar 

  23. Rozencweig, M., Slavik, M., Muggia, F. M., Carter, S. K.: Overview of early and investigational chemotherapeutic agents in solid tumors. Med. Ped. Oncology 2, 417–432 (1976).

    Article  CAS  Google Scholar 

  24. Slavik, M., Carter, S. K.: Chromomycin A3, mithramycin, and olivomycin: Antitumor antibiotics of related structure. Adv. Pharmacol. Chemother. 12, 1–30 (1975).

    Article  PubMed  CAS  Google Scholar 

  25. Tan, C. T. C., Golbey, R. B., Yap, C. L., Wollner, N., Hackethal, C. A., Murphy, L. M., Dargeon, H. W., Burchenal, J. H., Clinical experiences with actinomycins D, KS2, and F1 (KS4). Ann. N. Y. Acad. Sci. 89, 426–444 (1960).

    Article  PubMed  CAS  Google Scholar 

  26. Vertogradova, T. P., Goldberg, L. Y., Filipposyants, S. T., Belova, I. P., Stepanova, E. G., Shepelevtseva, N. G.: Mechanism of the toxic effect of the antitumor antibiotic, carminomycin. Antibiotiki 19, 50–57 (1974).

    PubMed  CAS  Google Scholar 

  27. Von Hoff, D. D., Rozencweig, M., Slavik, M., Muggia, F. M.: Activity of daunomycin in solid tumors. J. Am. Med. Assoc. 236, 1693 (1976).

    Google Scholar 

  28. Von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., Muggia, F. M.: Daunomycin-induced cardiotoxicity in children: A review of 110 cases. Am. J. Med. 62, 200–208 (1977).

    Article  Google Scholar 

  29. Von Hoff, D. D., Rozencweig, M., Soper, W. T., Helman, L. J., Penta, J. S., Davis, H.L., Muggia, F. M.: Whatever happened to NSC-? Cancer Treat. Rep. 61, 759–768 (1977).

    Google Scholar 

Download references

Authors
  1. F. M. Muggia
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California Cancer Program, 1801 Page Mill Road, Bldg. B, Suite 200, Palo Alto, California, 94304, USA

    S. K. Carter (Director) (Director)

  2. Department of Antibiotics, National Institutes of Health, Kami-Osaki 2-10-35, Shinagawa-ku, Tokyo, 1411, Japan

    Hamao Umezawa (Head) (Head)

  3. Division of Cancer Treatment, National Cancer Institute, Blair Bldg. Room 4A15, 8300 Colesville Road, Silver Spring, Maryland, 20910, USA

    John Douros

  4. Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Kami-Ikebukuro 1-37-1, Toshima-ku, Tokyo, Japan

    Yoshio Sakurai (Director) (Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1978 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Muggia, F.M. (1978). Clinical Evaluation of New Antitumor Antibiotics. In: Carter, S.K., Umezawa, H., Douros, J., Sakurai, Y. (eds) Antitumor Antibiotics. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 63. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81219-4_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-81219-4_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-81221-7

  • Online ISBN: 978-3-642-81219-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation